The antibody was purified by affinity chromatography.
Concentration:
0.5 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C.
Application:
ELISA Capture1-4 - Quality tested IHC5,6*, WB * - *This application has been reported in the literature.
Recommended Usage:
Each lot of this antibody is quality control tested by ELISA assay. For ELISA applications, a concentration range of 1-4 μg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
ELISA or ELISPOT Capture1-4: The purified JES3-19F1 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502/501503) as the detecting antibody. The LEAF™ purified antibody is suggested for ELISPOT capture. Neutralization1,2: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm sterile-filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. No. 506810). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining5,6 of paraformaldehyde-fixed, saponin-treated frozen tissue sections, and immunocytochemistry. Note: For testing human IL-10 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430601 to 430606) are specially developed and recommended.
Application References:
1. Abrams, J., et al., 1992. Immunol. Rev. 127: 5. 2. Gotlieb, W., et al., 1992. Cytokine 4: 385. 3. Yssel, H., et al., 1992. J. Immunol. 149: 2378. 4. Burdin, N., et al., 1993. J. Exp. Med. 177: 295. 5. Andersson, U., et al., 1999. Detection and quantification of gene expression. New York: Springer-Verlag. 6. Andersson, J., et al., 1994. Immunology 83: 16.
Description:
IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production. The JES3-19F1 antibody reacts with human and viral interleukin-10 (IL-10). The JES3-19F1 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Other Names:
Interleukin-10, B cell derived T cell growth factor (B-TCGF), Cytokine synthesis inhibitory factor (CSIF), T-cell growth inhibitory factor (TGIF)
Structure:
Acid-labile cytokine; dimer; 35-40 kD (Mammalian)
Regulation:
Production inhibited by IL-4, IL-10
Cellular Sources:
Activated CD8+ and CD4+ T cells, activated monocytes, mast cells, Ly-1 B (mouse)
Cellular Targets:
T cells, B cells, mast cells, macrophages
Receptors:
IL-10R (CDw210)
Bioactivity/Activities:
Inhibit IFN-γ, TNF-β, IL-2 production by TH1 clones; inhibits macrophage-mediated IL-1, IL-6, TNF-α synthesis; suppress delayed type hypersensitivity response; stimulate TH2 cell response; mast cell proliferation in
Antigen References:
1. Fitzgerald, K., et al., Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. de Waal-Malefyt, R., et al., 1992. Curr. Opin. Immunol. 4:314. 3. Howard, M., et al., 1992. Immunol. Today. 13:198. 4. Quesniaux, V. 1992. Research Immunol. 143:385.
